 The FDA issued a Complete Response Letter regarding the marketing application for Acer Therapeutics Inc NASDAQ: ACER and its collaboration partner, Relief Therapeutics Holding SAs OTC: RLFTF ACER-001 sodium phenylbutyrate, for urea cycle disorders UCDs. 